From: Jeffrey Epstein <[email protected]>

From: Jeffrey Epstein <[email protected]> To: Alice Jacobs Subject: Re: IMDx Enters into Agreement with Abbott Date: Fri, 21 Jan 2011 12:00:02 +0000 great .. im proud of you On Thu, Jan 20, 2011 at 5:28 PM, Alice Jacobs 1 wanted to update you with our latest news. I hope that you're doing well. My best, Alice > wrote: Intelligent Medical Devices, Inc. (IMDx) Enters into an Agreement with Abbott for the Distribution of a Broad Menu of Molecular Tests Cambridge, MA January 20, 2011— IMDx (privately held) today announced that they have signed a multi-year agreement with Abbott whereby IMDx will design, develop, regulatory clear, and manufacture assays for the Abbott Molecular FDA cleared, m2000 instrument system to be distributed worldwide. Financial terms have not been disclosed. IMDx tests are state of the art incorporating important and evolving clinical needs. The tests are designed utilizing IMDx's proprietary bioinformatics process which ensures high performing products that are optimized and in silico verified. Tests will include identification of the following infectious organisms, Clostridium difficile, Vancomycin- Resistance Enterococci (VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus 1 and 2 (HSV 1/2). In addition, two additional tests will be commercialized for use outside the United States for the determination of viral load for Epstein-Barr virus (EBV) and BK Virus (BKV). 'We are extremely pleased to capture the synergies between IMDx and Abbott and to be able to offer these important tests to patients globally. The test areas under this agreement directly address a major unmet need in the clinical lab: high quality tests that are FDA cleared if for US sales. Early identification of these pathogens can help improve patient healthcare, shorten treatments, and reduce expense," says Alice Jacobs, MD, Chairman & CEO of IMDx. 'This agreement, which demonstrates Abbott Molecular's commitment to menu expansion on the m2000 system, will allow customers to gain access to a broad menu of FDA and internationally marketed assays, that are available on a single automated instrument system," says Stafford O'Kelly, head of Abbott's molecular diagnostics business. About IMDx Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs. EFTA00902109 Media: IMDx Corporate Communications: 617-871-6417 Alice A. Jacobs, M. Chairman 8 CEO IntelIigentMDx 19 Blackstone Street Cambridge, MA 02139 Phone: (617) 871.6406 Cell: (617)953-3210 Fax: (617) 871-6440 Email: Visit us at The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. My review, retransmission, dissemination or other use of. or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from all computers. The information contained in this communication is EFTA00902110 confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA00902111